CN103718046B - 预测不良临床结果的风险的方法 - Google Patents

预测不良临床结果的风险的方法 Download PDF

Info

Publication number
CN103718046B
CN103718046B CN201280023965.1A CN201280023965A CN103718046B CN 103718046 B CN103718046 B CN 103718046B CN 201280023965 A CN201280023965 A CN 201280023965A CN 103718046 B CN103718046 B CN 103718046B
Authority
CN
China
Prior art keywords
galectin
subject
levels
level
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280023965.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103718046A (zh
Inventor
J.V.斯奈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Critical Care Diagnostics Inc
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Priority to CN201610825849.1A priority Critical patent/CN106940375B/zh
Publication of CN103718046A publication Critical patent/CN103718046A/zh
Application granted granted Critical
Publication of CN103718046B publication Critical patent/CN103718046B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201280023965.1A 2011-03-17 2012-03-16 预测不良临床结果的风险的方法 Expired - Fee Related CN103718046B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610825849.1A CN106940375B (zh) 2011-03-17 2012-03-16 预测不良临床结果的风险的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453782P 2011-03-17 2011-03-17
US61/453,782 2011-03-17
PCT/US2012/029500 WO2012141844A2 (en) 2011-03-17 2012-03-16 Methods predicting risk of an adverse clinical outcome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610825849.1A Division CN106940375B (zh) 2011-03-17 2012-03-16 预测不良临床结果的风险的方法

Publications (2)

Publication Number Publication Date
CN103718046A CN103718046A (zh) 2014-04-09
CN103718046B true CN103718046B (zh) 2016-10-12

Family

ID=47009907

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610825849.1A Expired - Fee Related CN106940375B (zh) 2011-03-17 2012-03-16 预测不良临床结果的风险的方法
CN201280023965.1A Expired - Fee Related CN103718046B (zh) 2011-03-17 2012-03-16 预测不良临床结果的风险的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610825849.1A Expired - Fee Related CN106940375B (zh) 2011-03-17 2012-03-16 预测不良临床结果的风险的方法

Country Status (6)

Country Link
US (4) US8728742B2 (enExample)
EP (2) EP2686689B1 (enExample)
JP (2) JP6215713B2 (enExample)
CN (2) CN106940375B (enExample)
ES (2) ES2897419T3 (enExample)
WO (1) WO2012141844A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
ES2573471T3 (es) 2002-05-09 2016-06-08 The Brigham And Women's Hospital, Inc. 1L1RL-1 como un marcador de enfermedades cardiovasculares
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
EP2021799B1 (en) * 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
EP2995951B1 (en) * 2006-05-02 2019-02-13 Critical Care Diagnostics, Inc. Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease
PT2827152T (pt) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
HRP20160461T1 (hr) 2010-04-09 2016-06-17 Critical Care Diagnostics, Inc. Solubilna humana st-2 antitijela i eseji
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
EP2734222B1 (en) 2011-07-18 2016-10-19 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
MX357740B (es) 2012-05-18 2018-07-23 Critical Care Diagnostics Inc Métodos para determinar el pronóstico del tratamiento de un sujeto con un desfibrilador cardíaco implantado, un dispositivo de tratamiento de resincronización cardíaca o un dispositivo combinado de desfibrilador cardíaco implantado y de resincronización cardíaca.
PL2885641T3 (pl) 2012-08-16 2018-04-30 Critical Care Diagnostics, Inc. Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi
MX375520B (es) 2012-08-21 2025-03-06 Critical Care Diagnostics Inc Estratificación de riesgo para marcador múltiple.
CN104521298B (zh) * 2013-08-08 2018-07-03 华为技术有限公司 传输信号的方法、网络侧设备和用户设备
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
EP3448245A4 (en) * 2016-04-25 2019-03-06 Siemens Healthcare Diagnostics Inc. DIAGNOSTIC PROCEDURE FOR DETECTING AND TREATING POST-INFARM MYOKARD REMODELING AND DIFFUSER MYOCARDIBLE FIBROSIS
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
RU2677611C1 (ru) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
CN113425271B (zh) * 2021-05-20 2024-02-06 上海小芃科技有限公司 日间手术出院判断方法、装置、设备及存储介质
WO2024092136A2 (en) * 2022-10-28 2024-05-02 Memorial Sloan-Kettering Cancer Center Machine learning modeling for inpatient prediction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155513A1 (en) * 1999-04-13 2002-10-24 Hsu Daniel K. Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
CN1543352A (zh) * 2001-06-22 2004-11-03 ����ƻ���ϵͳ��˾ 用于治疗免疫性疾病的方法和材料

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
PT1493439E (pt) 1997-04-02 2012-01-10 Brigham & Womens Hospital Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica
ATE489633T1 (de) 1997-06-10 2010-12-15 Lpath Inc Verfahren zum frühzeitigen nachweis herzerkrankungen
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
EP1140137A2 (en) 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (en) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
BR0107157A (pt) 2000-08-22 2002-07-16 Brigham And Womens Hospital In Diagnose e tratamento de condições cardiovasculares
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
ES2573471T3 (es) 2002-05-09 2016-06-08 The Brigham And Women's Hospital, Inc. 1L1RL-1 como un marcador de enfermedades cardiovasculares
AU2003299441A1 (en) 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
WO2004111654A2 (en) * 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
EP1522857A1 (en) 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US20050250156A1 (en) 2003-10-31 2005-11-10 Shebuski Ronald J Detection of acute myocardial infarction biomarkers
CA3050151C (en) 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
EP2021799B1 (en) 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
EP2995951B1 (en) 2006-05-02 2019-02-13 Critical Care Diagnostics, Inc. Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
EP2282757B1 (en) * 2008-04-07 2013-05-22 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
PT2827152T (pt) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
WO2010007041A1 (en) * 2008-07-14 2010-01-21 Roche Diagnostics Gmbh Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure
EP3971570A3 (en) * 2008-10-29 2022-11-09 BG Medicine, Inc. Galectin-3 immunoassay
HRP20160461T1 (hr) 2010-04-09 2016-06-17 Critical Care Diagnostics, Inc. Solubilna humana st-2 antitijela i eseji
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
EP2734222B1 (en) 2011-07-18 2016-10-19 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
MX357740B (es) 2012-05-18 2018-07-23 Critical Care Diagnostics Inc Métodos para determinar el pronóstico del tratamiento de un sujeto con un desfibrilador cardíaco implantado, un dispositivo de tratamiento de resincronización cardíaca o un dispositivo combinado de desfibrilador cardíaco implantado y de resincronización cardíaca.
PL2885641T3 (pl) 2012-08-16 2018-04-30 Critical Care Diagnostics, Inc. Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi
MX375520B (es) 2012-08-21 2025-03-06 Critical Care Diagnostics Inc Estratificación de riesgo para marcador múltiple.
MX2016009060A (es) 2014-01-10 2016-09-09 Critical Care Diagnostics Inc Metodos y sistemas para determinar el riesgo de falla cardiaca.
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155513A1 (en) * 1999-04-13 2002-10-24 Hsu Daniel K. Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
CN1543352A (zh) * 2001-06-22 2004-11-03 ����ƻ���ϵͳ��˾ 用于治疗免疫性疾病的方法和材料

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
心力衰竭治疗的新视野;廖玉华;《临床心血管病杂志》;20050131;第21卷(第1期);1-2 *
急性心力衰竭血液生化标志物临床研究近况;于浥淳等;《中国医药导报》;20100930;第7卷(第27期);13-14 *
慢性心力衰竭的循环生化标记物研究进展;刘文成等;《河北医药》;20101231;第32卷(第23期);3371-3372 *

Also Published As

Publication number Publication date
US20140234875A1 (en) 2014-08-21
JP6215713B2 (ja) 2017-10-18
WO2012141844A2 (en) 2012-10-18
CN103718046A (zh) 2014-04-09
CN106940375A (zh) 2017-07-11
US20120276551A1 (en) 2012-11-01
ES2897419T3 (es) 2022-03-01
US9823257B2 (en) 2017-11-21
CN106940375B (zh) 2019-03-08
US9239333B2 (en) 2016-01-19
US8728742B2 (en) 2014-05-20
EP3605104A1 (en) 2020-02-05
JP2014514536A (ja) 2014-06-19
WO2012141844A3 (en) 2013-03-21
EP2686689B1 (en) 2019-08-07
EP2686689A4 (en) 2014-09-03
EP2686689A2 (en) 2014-01-22
US20180292415A1 (en) 2018-10-11
JP2018021926A (ja) 2018-02-08
US10393756B2 (en) 2019-08-27
ES2750126T3 (es) 2020-03-25
EP3605104B1 (en) 2021-09-15
US20160299153A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
CN103718046B (zh) 预测不良临床结果的风险的方法
US10041957B2 (en) Methods for predicting risk of developing hypertension
JP2021039108A (ja) 主要有害心イベントのリスクを予測する方法
JP4741249B2 (ja) 心血管疾患における生化学的マーカーの組合せとしてのｓＣＤ４０Ｌ，ＰＡＰＰ−Ａおよび胎盤増殖因子（ＰｌＧＦ）
US20090305265A1 (en) Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
CN108982871B (zh) 血清sST2在小儿扩张型心肌病预后中的应用
HK1192619A (en) Methods predicting risk of an adverse clinical outcome
HK1192619B (en) Methods predicting risk of an adverse clinical outcome
CN116298306A (zh) Gas6蛋白作为心力衰竭心室重构、病情严重性及预后诊断标志物的应用
HK1212022B (en) Methods for predicting risk of developing hypertension
HK1208075B (en) Methods for predicting risk of developing hypertension

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192619

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1192619

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161012